| 000 | 01812 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517204901.0 | ||
| 264 | 0 | _c20190205 | |
| 008 | 201902s 0 0 eng d | ||
| 022 | _a1938-0682 | ||
| 024 | 7 |
_a10.1016/j.clgc.2018.02.013 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNouhaud, François-Xavier | |
| 245 | 0 | 0 |
_aClinical Relevance of Gene Copy Number Variation in Metastatic Clear Cell Renal Cell Carcinoma. _h[electronic resource] |
| 260 |
_bClinical genitourinary cancer _c08 2018 |
||
| 300 |
_ae795-e805 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 |
_aChromosomes, Human, Pair 6 _xgenetics |
| 650 | 0 | 4 |
_aChromosomes, Human, Pair 9 _xgenetics |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCyclin-Dependent Kinase Inhibitor p16 |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase Inhibitor p18 _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFructose-Bisphosphate Aldolase _xgenetics |
| 650 | 0 | 4 | _aGene Deletion |
| 650 | 0 | 4 | _aGene Dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPlasminogen _xgenetics |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aBlanchard, France | |
| 700 | 1 | _aSesboue, Richard | |
| 700 | 1 | _aFlaman, Jean-Michel | |
| 700 | 1 | _aSabourin, Jean-Christophe | |
| 700 | 1 | _aPfister, Christian | |
| 700 | 1 | _aDi Fiore, Frédéric | |
| 773 | 0 |
_tClinical genitourinary cancer _gvol. 16 _gno. 4 _gp. e795-e805 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clgc.2018.02.013 _zAvailable from publisher's website |
| 999 |
_c28188183 _d28188183 |
||